Retatrutide vs Tesofensine
A side-by-side research comparison of Retatrutide and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Retatrutide | Tesofensine |
|---|---|---|
| Full name | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Phase 3 Clinical Trial |
| Mechanism | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | 5,200 Da (approximate) | 329.4 Da |
| Half-life | 6 days | 8-10 days |
| Bioavailability | High (SubQ) | High (oral ~93%) |
| Typical dose | 1-2 mg → titrate up to 12 mg | 0.25-0.5 mg |
| Frequency | Once weekly | Once daily |
| Route | Subcutaneous injection | Oral |
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.